Patents Assigned to Pfizer
  • Orally active renin inhibitors
    Patent number: 5442044
    Abstract: This invention relates to compounds of the formula ##STR1## wherein Q, Z, D, E, R.sup.3, R.sup.4, R.sup.5 and R.sup.6 are defined as below, and the pharmaceutically acceptable salts thereof are disclosed. The compounds are useful as antihypertensive agents.
    Type: Grant
    Filed: March 8, 1993
    Date of Patent: August 15, 1995
    Assignee: Pfizer Inc.
    Inventors: Dennis J. Hoover, Bruce A. Lefker, Robert L. Rosati
  • Estrogen agonists as remedies for prostate and cardiovascular diseases
    Patent number: 5441986
    Abstract: Use of droloxifene in the treatment of benign prostatic hyperplasia, prostatic carcinoma and cardiovascular diseases.
    Type: Grant
    Filed: July 19, 1994
    Date of Patent: August 15, 1995
    Assignee: Pfizer Inc.
    Inventor: David D. Thompson
  • Process for preparing sertraline intermediates
    Patent number: 5442116
    Abstract: The invention provides the substantially geometrically and optically pure trans-stereoisomeric form of a compound of formula (I): ##STR1## wherein R.sup.1 is H or C.sub.1 -C.sub.4 alkyl, together with processes for its preparation. The compounds are intermediates for the preparation of the antidepressant agent known as sertraline.
    Type: Grant
    Filed: January 10, 1994
    Date of Patent: August 15, 1995
    Assignee: Pfizer Inc.
    Inventors: Willard M. Welch, Michael T. Williams
  • Bicyclic carbamates, pharmaceutical compositions and use
    Patent number: 5439929
    Abstract: The present invention relates to bicyclic carbamate compounds and, specifically, to compounds of the formula ##STR1## wherein X, Y, R.sup.1 and R.sup.2 are as defined in the specification. The compounds of this invention are useful in the treatment of asthma, rheumatoid arthritis, osteoarthritis, bronchitis, chronic obstructive airways disease, psoriasis, allergic rhinitis, atopic dermatitis, shock, other inflammatory diseases, and other conditions where the treatment is effected or facilitated by blocking the leukotriene D4 receptor.
    Type: Grant
    Filed: March 1, 1994
    Date of Patent: August 8, 1995
    Assignee: Pfizer Inc.
    Inventor: Matthew F. Brown
  • 3-aryl-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
    Patent number: 5438074
    Abstract: Certain 3-(phenyl, chroman-2-yl, benzofuran-5-yl or benzoxazol-5-yl)-2-(hydroxy or mercapto)propionic acid derivatives and analogs are useful as hypoglycemic and hypocholesterolemic agents.
    Type: Grant
    Filed: December 6, 1993
    Date of Patent: August 1, 1995
    Assignee: Pfizer Inc.
    Inventor: Bernard Hulin
  • 3-bromo-5-chloro-pyridines used as intermediates in the synthesis of azatetralones
    Patent number: 5436344
    Abstract: Compounds of the formula ##STR1## wherein R.sup.1 is hydrogen, fluoro, chloro, bromo, nitro, trifluoromethyl, C.sub.1 to C.sub.4 alkoxy, C.sub.1 to C.sub.4 alkylthio or C.sub.1 to C.sub.6 alkyl and R.sup.2 is a group of the formula ##STR2## wherein R.sup.3 is hydrogen or C.sub.1 to C.sub.6 alkyl, R.sup.4 is --CH.dbd.C.sub.2, --CH.sub.2 --YR.sup.5, or --COR.sup.6, R.sup.5 is hydrogen or an acid labile alcohol protecting group, Y is oxygen or sulfur, and R.sup.6 is --NR.sup.7 R.sup.8 or --OR.sup.9 wherein R.sup.7, R.sup.8 and R.sup.9 are independently selected from hydrogen or C.sub.1 to C.sub.6 alkyl, or an alkaline or alkaline earth metal salt thereof, which are intermediates in the preparation of hydantoin aldose reductase inhibitors and methods of preparing these intermediates.
    Type: Grant
    Filed: March 18, 1994
    Date of Patent: July 25, 1995
    Assignee: Pfizer Inc.
    Inventor: George J. Quallich
  • Method of treating diseases susceptable to treatment by blocking NMDA-receptors
    Patent number: 5436255
    Abstract: 3-Piperidino-1-chromanol derivatives and analogs having the formula ##STR1## wherein A and B are taken together and are --CH.sub.2 CH.sub.2 -- or A and B are taken separately and are each H;X is CH.sub.2 or O;X.sup.1 is H or OH;Z is H, F, Cl, Br or OH;Z.sup.1 is H, F, Cl, Br or (C.sub.1 -C.sub.3)alkyl;n is 0 or 1; andm is 0 or an integer from 1 to 6;pharmaceutical compositions thereof; methods of treating CNS disorders therewith; and intermediates useful in the preparation of said compounds are disclosed.
    Type: Grant
    Filed: March 14, 1994
    Date of Patent: July 25, 1995
    Assignee: Pfizer Inc.
    Inventor: Todd W. Butler
  • Intermediates in the preparation of 4,5-difluoroanthranillic acid
    Patent number: 5436368
    Abstract: Compounds of the formula ##STR1## which are intermediates in the preparation of 4,5-difluoroanthranilic acid, an intermediate itself in the synthesis of quinolone antibacterials, and methods of preparing these intermediates.
    Type: Grant
    Filed: November 14, 1994
    Date of Patent: July 25, 1995
    Assignee: Pfizer Inc.
    Inventor: Tamim F. Braish
  • Use of rapamycin prodrugs as immunosuppressant agents
    Patent number: 5432183
    Abstract: The use of rapamycin prodrugs of formula I as immunosuppressant agents, intermediates formed in the preparation of its prodrugs as well as the prodrugs themselves.
    Type: Grant
    Filed: November 30, 1993
    Date of Patent: July 11, 1995
    Assignee: Pfizer Inc.
    Inventor: Gary R. Schulte
  • Dispensing device containing a hydrophobic medium
    Patent number: 5431921
    Abstract: A device for the controlled delivery of an insoluble or partially aqueous insoluble beneficial agent to an aqueous containing environment. The device comprises a shaped wall that surrounds and defines an internal reservoir. The wall is formed at least in part of a sintered polymer microporous membrane permeable to a beneficial agent-containing hydrophobic medium when the wall is present in the aqueous containing environment. The reservoir contains a mixture of a hydrophilic swellable composition and a beneficial agent-containing hydrophobic medium.
    Type: Grant
    Filed: March 12, 1993
    Date of Patent: July 11, 1995
    Assignee: Pfizer Inc
    Inventor: Avinash G. Thombre
  • Inhibitor of squalene synthase
    Patent number: 5430055
    Abstract: The culture ATCC 74256 and its mutants are capable of producing zaragozic acid A and other squalene synthase inhibitors.The compound of formula I herein may be prepared from culture ATCC 74256 and is useful in the treatment of fungal infections, and inhibition of squalene synthase, and protein farnesyltransferase.
    Type: Grant
    Filed: April 8, 1994
    Date of Patent: July 4, 1995
    Assignee: Pfizer Inc.
    Inventors: Thomas T. Dabrah, H. James Harwood, Jr., Liang H. Huang, Takushi Kaneko
  • Tricyclic-cyclic amines as novel cholinesterase inhibitors
    Patent number: 5428043
    Abstract: Compounds of the formula ##STR1## wherein ring A, ring B, ring D, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6,R.sup.11, R.sup.12, R.sup.13, E, G, X and P are as defined below. The compounds of formula I are cholinesterase inhibitors and are useful in enhancing memory in patients suffering from dementia and Alzheimer's disease.
    Type: Grant
    Filed: October 29, 1992
    Date of Patent: June 27, 1995
    Assignee: Pfizer Inc.
    Inventor: Yuhpyng L. Chen
  • Pyrazolopyrimidinone antianginal agents
    Patent number: 5426107
    Abstract: Compounds of the formula ##STR1## and pharmaceutically acceptable salts thereof are selective cGMP PDE inhibitors which are useful in the treatment of such diseases and adverse conditions as angina, hypertension, congestive heart failure, reduced blood vessel patency, peripheral vascular disease, stroke, bronchitis, chronic asthma, allergic asthma, allergic rhinitis, glaucoma, and diseases characterized by disorders of gut motility.
    Type: Grant
    Filed: July 23, 1993
    Date of Patent: June 20, 1995
    Assignee: Pfizer Inc.
    Inventors: Andrew S. Bell, Nicholas K. Terrett
  • Quinuclidine derivatives
    Patent number: 5422354
    Abstract: Quinuclidine derivatives of the formula ##STR1## and the pharmaceutically acceptable salts thereof, wherein m, P, Z, Y, R.sup.1, R.sup.2 and R.sup.3 are as defined below. The compounds are substance P antagonists and, therefore, are useful in treating gastrointestinal disorders, central nervous system disorders, inflammatory diseases, pain and migraine.
    Type: Grant
    Filed: February 1, 1993
    Date of Patent: June 6, 1995
    Assignee: Pfizer Inc
    Inventor: John A. Lowe, III
  • Muscarinic receptor antagonists
    Patent number: 5422358
    Abstract: Compounds of the formula ##STR1## and the pharmaceutically acceptable salts thereof, wherein: Y is a direct link, --CH.sub.2 --, --(CH.sub.2).sub.2 --, --CH.sub.2 O-- or --CH.sub.2 S--; R is --CN or --CONH.sub.2 ; and R.sup.1 is ##STR2## where X and X.sup.1 are each independently O or CH.sub.2 ; and m is 1, 2 or 3, are muscarinic receptor antagonists useful in the treatment of diseases and conditions associated with the altered motility and/or tone of smooth muscle, such as irritable bowel syndrome.
    Type: Grant
    Filed: April 29, 1991
    Date of Patent: June 6, 1995
    Assignee: Pfizer Inc
    Inventors: Peter E. Cross, Alexander R. Mackenzie
  • Resolution of (R)-2-benzylsuccinic acid 4-[4-(N-t-butoxycarbonylmethylamino)-piperidine] amide
    Patent number: 5420283
    Abstract: This invention relates to with a novel synthesis of (R)-2-benzylsuccinic acid 4-[4-(N-t-butoxycarbonyl-methylamino)-piperidine]amide from racemic intermediates. The racemic (R)-2-benzylsuccinic acid 4-[4-(N-t-butoxycarbonyl-methylamino)piperidine]amine is resolved through the formation of diasteromic salts with (S)-cyclohexylethylamine or (R)-cyclohexylethylamine. The pure diasteromic salt can be subsequently hydrolyzed with dilute acid to yield the pure enantiomer of (R)-2-benzylsuccinic acid 4-[4-(N-t-butoxycarbonyl-methylamino) piperidine]amide.
    Type: Grant
    Filed: August 2, 1993
    Date of Patent: May 30, 1995
    Assignee: Pfizer Inc.
    Inventor: Robert W. Dugger
  • Processes and intermediates for N-(S-3-alkyl-heptanoyl)-D-gamma-glutamyl-glycyl-D-alanine
    Patent number: 5420347
    Abstract: Immunoregulatory N-(S-3-alkyl-4-heptenoyl)- and N-(S-3-alkylheptanoyl)-D-gamma-glutamyl-glycyl-D-alanine and esters thereof are synthesized via R-trans-2-hexen-4-ols, R-3-alkyl-4-heptenoic acid and S-3-alkylheptanoic acid.
    Type: Grant
    Filed: December 1, 1993
    Date of Patent: May 30, 1995
    Assignee: Pfizer Inc.
    Inventor: Charles W. Murtiashaw
  • Pyrimido-benzothiazines
    Patent number: 5418231
    Abstract: This invention relates to novel pyrimido-benzothiazine derivative compounds. ##STR1## The compounds of the present invention inhibit the action of the lipoxygenase enzyme and are useful in the treatment or alleviation of inflammatory diseases, allergy and cardiovascular diseases in mammals. This invention also relates to pharmaceutical compositions comprising such compounds.
    Type: Grant
    Filed: June 28, 1993
    Date of Patent: May 23, 1995
    Assignee: Pfizer Inc.
    Inventors: Kaoru Shimada, Yuji Shishido
  • Acidic polycyclic ether antibiotic
    Patent number: 5418152
    Abstract: An acidic polycyclic ether antibiotic, having structure established by X-ray crystallography, is formed by fermentation of a novel microorganism, Actinomadura sp. ATCC 55080. This novel antibiotic is useful as an anticoccidial in poultry, in the prevention and treatment of swine dysentery and as a growth promotant in cattle and swine.
    Type: Grant
    Filed: March 12, 1993
    Date of Patent: May 23, 1995
    Assignee: Pfizer Inc
    Inventors: Walter P. Cullen, John P. Dirlam, Hiroshi Maeda, Junsuke Tone
  • Instrumentation for preparing a distal femur
    Patent number: 5417695
    Abstract: A method and apparatus for preparing a planar surface on the distal femur prior to implantation of a femoral knee prosthesis has a femoral plate with an opening therein for exposing both condyles of the femur. A guide with a central aperture is used to align the femoral plate on the distal femur. The guide is releasably secured to the femoral plate and an intramedullary guide rod is placed through the aperture therein and into the intramedullary canal of the femur. After alignment with the intramedullary canal, the femoral plate is pinned to the femur and the rod and guide are removed. A milling guide having two bores, one adjacent each condyle, is then placed on the femoral plate and an end mill is used to mill a planar surface on at least one of the condyles.
    Type: Grant
    Filed: July 27, 1992
    Date of Patent: May 23, 1995
    Assignee: Pfizer Hospital Products Group, Inc.
    Inventor: Stuart L. Axelson, Jr.